Interim FDA-Mandated Postmarket Study Finds Essure Has Significantly Higher Rates Of Adverse Events

 
• By Ferdous Al-Faruque
  
BERLIN, FEBRUARY 2: Pedestrian bridge over the street on the Bayer Headquarters in Berlin on February 2, 2016.
Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Regulation

More from Policy & Regulation